Cardiac Imaging 2015: A Selection of Topical Issues

Selección de temas de actualidad en imagen cardiaca 2015

CrossMark

Teresa López-Fernández,[a,*] Daniel Saura,[b] José F. Rodríguez-Palomares,[c] Santiago Aguadé-Bruix,[d] Leopoldo Pérez de Isla,[e] and Joaquín Barba-Cosials[f]

[a] *Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain*
[b] *Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain*
[c] *Servicio de Cardiología, Hospital Universitari Vall d'Hebron, Institut de Recerca-VHIR, Universitat Autónoma de Barcelona, Barcelona, Spain*
[d] *Servicio de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Barcelona, Spain*
[e] *Servicio de Cardiología, Hospital Clínico Universitario San Carlos, Madrid, Spain*
[f] *Departamento de Cardiología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain*

ECHOCARDIOGRAPHY

Developments in Echocardiography

The beginning of the year saw the publication of new recommendations on echocardiographic quantification, proposing interesting changes regarding normal cutoff values, volume quantification, recommendations on 3-dimensional echocardiography, and deformation parameters.[1] Other published documents included recommendations on the assessment of patients with cancer[2] and acute patients[3] as well as recommendations on echocardiography in hypertension.[4]

The Spanish Society of Cardiology, through their Department of Cardiac Imaging, issued a recommendation document on the appropriate use of handheld echocardiography devices[5] (Table).

Technological developments included several studies that presented the possibility of obtaining models of various diseases—particularly congenital diseases—using 3-dimensional printing, with data from 3-dimensional echocardiography or other techniques.[6,7] There were also advances is the fusion of echocardiographic and fluroscopic imaging in the areas of coronary angiography[8] and interventional techniques.[9]

Myocardial Perfusion With Contrast and Stress Echocardiography

From an experimental point of view, there was continued discussion on the possibility of marking cells with contrast agents[10] and of using microbubbles for therapeutic purposes, incorporating drugs that can be released and activate therapeutic targets.[11]

Despite the emergence of new contrasts[12] and new evidence on their advantages,[13] perfusion techniques have not yet been incorporated as an everyday echocardiography tool.

Stress echocardiography further increased its scope of activity beyond ischemic heart disease: use of this technique is encouraged in heart failure with preserved ejection fraction[14] and in

valvular heart disease.[15] There was also greater interest in the study of diastolic function reference values in stress echocardiography.[16]

Echocardiographic calcium score after stress echocardiography was demonstrated to have a predictive value for events during follow-up.[17] New analyses recommend not screening for ischemic heart disease with ischemia detection tests, including stress echocardiography, in asymptomatic low-risk patients.[18]

Three-dimensional Echocardiography

One of the most interesting developments of 2015 was the publication of the updated recommendations on the use of transesophageal echocardiography. There was particular emphasis on the usefulness of this technique as a support to structural interventions, with significant reference to 3-dimensional transesophageal echocardiography.[19] Furthermore, 3-dimensional echocardiography was established as advantageous and as the gold standard for the study of various aspects of cardiac anatomy and function: in one study,[20] 3-dimensional echo was able to determine the dynamics of the calcified mitral annulus.

Regarding advances in myocardial deformation assessment, the studies of note were those published on the usefulness of 3-dimensional data sets; this technique received as much support as criticism.[21,22] One interesting study showed the potential of new parameters obtained from 3-dimensional echocardiography, in the form of propagation imaging of left ventricular activation.[23] It was also a productive year in the area of atrial mechanics assessment. The possibility of analyzing not only ventricular myocardial deformation but also atrial myocardial deformation[24] was strengthened, and atrial volume is known to be an excellent prognostic marker in various heart diseases[25] (Figure 1).

Interventions

One of the previously little-explored fields in the role of imaging in structural interventions was percutaneous closure of interventricular septal defects. A notable study showed 3-dimensional echocardiography to be a highly useful tool in this procedure.[26] Regarding percutaneous closure of the atrial appendage, an excellent review article makes recommended reading, detailing echocardiographic assessment and the clinical implications of the findings regarding the left atrial appendage.[27] One article outlined a new proposal to measure the dimensions of the left atrial appendage using transesophageal echocardiography.[28] Another

* Corresponding author: Laboratorio de Imagen Cardiaca, Servicio de Cardiología, Hospital Universitario La Paz, Hospital General, Planta primera, P.° de la Castellana 261, 28046 Madrid, Spain.
E-mail address: tlfernandez8@gmail.com (T. López-Fernández).

<div style="border: 1px solid red">

Abbreviations

CMR: cardiac magnetic resonance
AS: aortic stenosis
PLGAS: paradoxical low gradient aortic stenosis
PET: positron emission tomography
SPECT: single-photon emission computed tomography
CT: computed tomography

</div>

Table
Indications for the Use of Hand-held Equipment

1.	Complementary to physical examination in the coronary care unit or intensive care unit
2.	Initial screening in the emergency department
3.	Cardiac consultation, outpatient or inpatient
4.	Initial assessment in ambulance
5.	Population screening programs
6.	Selection of candidates for complete echocardiographic examination
7.	Undergraduate and specialty training
8.	Semi-quantitative evaluation of extravascular pulmonary fluid

Reproduced with permission from Barba et al.[5]

article described the usefulness of complementary information obtained from cardiac computed tomography (CT) and echocardiography.[29] Regarding percutaneous closure of periprosthetic dehiscence, a noteworthy article addressed the subject of communication between interventionalists and echocardiographers in this type of procedure.[30]

Valvular Heart Disease

A subject attracting much attention in the field of valvular disease was quantification of aortic stenosis (AS) in patients with a paradoxical low gradient aortic stenosis (PLGAS). One of the limitations in calculating the aortic valve area by echocardiography is quantifying the area of the left ventricular outflow tract. The Leiden group contributed an original study in which they combined information from echocardiography and CT, in a population of 191 patients with severe AS on echocardiography. These authors quantified the aortic valve area by combining information from Doppler with measurement of the left ventricular outflow tract on CT. With this combination of techniques, 52% of patients with a diagnosis of severe AS with normal flow and low gradient and 12% of patients with severe AS with low flow and low gradient were reclassified as having moderate AS.[31] Paradoxical low gradient aortic stenosis was established as a distinct clinical entity. The Pellika group retrospectively explored the clinical course of patients with PLGAS. The study included 1203 patients with an aortic valve area < 1 cm^2 and ejection fraction > 50%, of whom 78 patients met the criteria for PLGAS,

and only 5% had had a previous study with severe AS and high gradient.[32] The authors concluded that PLGAS is not necessarily the final stage of AS, but is an entity with specific myocardial and hemodynamic changes. Although the patients with PLGAS had a preserved ejection fraction, they had intrinsic systolic dysfunction, as demonstrated on measurement of global longitudinal strain, which has been shown to affect both prognosis[33,34] and functional capacity.[35] Furthermore, following transcatheter aortic valve implantation (TAVI) in patients with PLGAS, transprosthetic flow was found to remain low despite the increase in the effective valve area, as a consequence of permanently elevated systemic vascular resistance.[36] The complex relationship between the progressive decrease in aortic valve area and the myocardial and vascular changes can lead to a low stroke volume. The stroke volume index was confirmed as an echocardiographic measurement with strong prognostic value across a range of values.[37]

Three-dimensional techniques have shown usefulness in the assessment of candidate patients for TAVI. Due to the development of new quantification tools, it is now possible to perform automatic reproducible measurements of the aortic annulus throughout the cardiac cycle.[38] The superiority of echocardiography over CT in the selection of candidates for direct TAVI was also demonstrated.[39] New prostheses have reduced the incidence of peri-TAVI aortic regurgitation; however, quantification of this regurgitation still has prognostic implications. As in native aortic regurgitation,

Figure 1. Quantification of left atrial volume by 3-dimensional transthoracic echocardiography.

Figure 2. Receiver operating characteristic curves of measurements of effective regurgitant orifice and anatomical regurgitant orifice with 3-dimensional color echography. Effective regurgitant orifice was the best predictor for correct diagnosis of moderate or severe paravalvular regurgitation. 3D-ARO, anatomical regurgitant orifice measured on 3-dimensional echocardiography with color Doppler; 3D-color-ERO, effective regurgitant orifice measured on 3-dimensional echocardiography with color Doppler. Reproduced with permission from Franco et al.[4]

cardiac magnetic resonance (CMR) was shown to be a useful technique in these patients.[40,41]

The development of 3-dimensional transesophageal echocardiography has improved anatomical assessment of the mitral valve[42] and allows quantification and understanding of mitral valve apparatus remodeling in patients with functional mitral regurgitation.[43] Three-dimensional transesophageal echocardiography was also established as a key part in the selection of candidates for complex percutaneous treatments, such as closure of periprosthetic dehiscence. The best parameter for predicting the degree of regurgitation and selecting the closure device was the effective regurgitant orifice area quantified with 3-dimensional transesophageal color echocardiography.[44] (Figure 2).

Aortic Disease

One article that stood out for its attention to the management of aortic disease was the joint document of the American Society of Echocardiography and the European Association of Cardiovascular Imaging on the multimodal diagnostic approach, integrating the information provided by each technique. It should undoubtedly be a reference document for any cardiologist interested in this type of disease.[45]

Ventricular Function

Technological advances have made it necessary to revise the normal parameters of systolic and diastolic ventricular function[46] and reevaluate the growing role of deformation techniques in various clinical scenarios.[47,48] Until now, differences between devices have prevented these techniques from becoming widespread. This year, a consensus document of the European Association of Cardiovascular Imaging/the American Society of Echocardiography/Industry[49] was published to standardize

2-dimensional strain quantification, thus allowing its increased clinical use.[50]

Cardiomyopathies

Echocardiography is a key tool in the assessment of athletes,[51] as well as in the management of cardiomyopathies.[52] In patients with hypertrophic cardiomyopathy, abnormalities in segmental contractility during exercise add prognostic value to the baseline study.[53] Quantification of ventricular deformation also adds prognostic value[54] and helps in the differential diagnosis of cardiac disease in infiltrative diseases.[55] Another important area of growing interest was cardio-oncology. Imaging techniques are an essential tool in the diagnosis of cardiotoxicity and in the monitoring of oncological treatment (Figure 3).[2] The developments in this area were the registries that contain a large number of patients with long-term follow-up, which continue to clarify doubts raised by smaller studies (such as the 9% incidence of ventricular dysfunction after the use of anthracyclines at 1 year).[56] Monitoring of global longitudinal strain throughout chemotherapy was shown to allow the early diagnosis of subclinical myocardial damage.[57] One study showed that 1 of every 3 cancer survivors had an abnormal global longitudinal strain,[58] and only early treatment of these patients with beta-blockers and angiotensin-converting enzyme inhibitors improved the chance of recovery.[59]

Heart Failure

Optimal use of imaging techniques is essential in the diagnosis, treatment planning, and follow-up of patients with heart failure.[60] Interesting studies were published on the role of deformation techniques in risk stratification of patients with heart failure and left ventricular ejection fraction > 50%.[61,62] It seems that these techniques will provide a new opportunity to study ventricular asynchrony with echocardiography.[63]

Figure 3. Flowchart from the guidelines of the American Society of Echocardiography/European Association of Cardiovascular Imaging on monitoring of adult patients with cancer. 3D, 3-dimensional echocardiography; GLS, global longitudinal strain; LLN, lower limit of normality according to equipment used; LVEF, left ventricular ejection fraction. These parameters identify patients at risk of ventricular dysfunction. [a]Echocardiographic study according to the clinical practice guidelines of the American Society of Echocardiography/European Association of Cardiovascular Imaging. [b]Starting treatment with angiotensin-converting enzyme inhibitors/beta-blockers is recommended. [c]There are few data that support starting beta-blockers and angiotensin-converting enzyme inhibitors to prevent ventricular remodeling. Adapted with permission from Plana et al.[2].

CARDIAC MAGNETIC RESONANCE IMAGING

Cardiac magnetic resonance is the technique of choice for assessment after acute myocardial infarction. In the acute phase of the infarct, the time elapsed between administering the contrast and acquiring the late enhancement sequences is crucial in quantifying the necrotic mass. During this phase, gadolinium can be retained in the myocardial area at risk, due to the presence of edema and inflammation, and can have slower clearance kinetics than the remote myocardium. Therefore, it is recommended to wait 20 min to 25 min between administering contrast and acquiring viability sequences.[64] This point is critical, as myocardial necrosis determination is used as a substitute variable in studies evaluating reperfusion strategies and as a prognostic variable of adverse events during follow-up. One randomized double-blind study demonstrated that the administration of intracoronary adenosine did not significantly reduce the size of necrosis compared with placebo.[65] The most significant predictors of major cardiovascular events were reduced systolic function ($< 47\%$), extensive necrosis ($> 19\%$ of myocardial mass), and microvascular obstruction.[66,67]

Stress CMR was established as an excellent technique for the diagnosis of ischemia. A meta-analysis that evaluated different noninvasive techniques in the diagnosis of significant coronary disease (by coronary angiography and fractional flow reserve) demonstrated that CMR, positron emission tomography (PET) and CT had higher sensitivity than single photon emission CT (SPECT) or stress echocardiography.[68]

Another field of interest in CMR was the assessment of cardiomyopathy. Chan et al[69] demonstrated, in 1293 patients followed-up for 3.3 years, that myocardial fibrosis of $> 15\%$ of the myocardial mass doubled the risk of sudden death compared with that in patients without fibrosis. In patients with myocarditis, T2

mapping sequences showed higher sensitivity and positive predictive value than biopsy in the diagnosis of active myocarditis.[70]

COMPUTED TOMOGRAPHY

Computed tomography was confirmed as an excellent option for the diagnosis of coronary artery disease in patients with an intermediate probability (20%-90%) of ischemic heart disease. The EVINCI study compared CT, SPECT/PET, CMR, and stress echography ± fractional flow reserve in 30% to 70% stenoses. The results showed that CT had a sensitivity of 91% and specificity of 92%, which were higher than those of the other investigational techniques.[71] The growing technological development and the combination of stress protocols has improved diagnostic accuracy. In the CORE320 study,[72] stress CT improved the accuracy of conventional CT in the diagnosis of significant coronary artery disease (Figure 4). However, stress CT has not yet replaced conventional ischemia detection techniques.

The PROMISE study[73] demonstrated that, in patients with suspected coronary artery disease, assessment with CT had the same predictive value for adverse events as other functional investigations over a follow-up of 2 years. Studies such as the CAPP trial[74] demonstrated that CT improved diagnostic accuracy in the assessment of symptomatic patients with suspected coronary disease. In patients with coronary artery disease who underwent CT, planned interventions were changed in 15%, the treatment regimen was changed in 25%, and the rate of events was reduced,[75] compared with conventional management.

Computed tomography is an excellent technique in the assessment of the aortic annulus and vascular access of candidate patients for TAVI. Valve calcium score (> 1274 Agatston units in women and > 2065 Agatston units in men) was associated with higher mortality in patients with medically treated severe AS.[76]

Figure 4. Stress-rest computed tomography showing diffuse coronary disease, predominantly in the left anterior descending artery and the right coronary artery, associated with a large antero-apical and inferior perfusion defect (above) with complete reversibility at rest (below).

NUCLEAR MEDICINE

Myocardial Perfusion

Recently, 2 large series were published, evaluating the role of myocardial perfusion studies. Romero-Farina et al[77] defined the warrantee period of a normal myocardial perfusion SPECT (period of remaining low-risk [< 1% events/year] regarding need for repeat investigation during that period) in a series with 3000 normal studies, with a follow-up of 5 years. These authors concluded that this period depended on the clinical characteristics of the patient, the type of stress test performed, and the left ventricular ejection fraction. This same group analyzed differences by sex in the predictive value of stress-rest gated SPECT, in 2414 patients (1438 women).[78]

Multimodal Imaging

Pizzi et al[79] evaluated the usefulness of SPECT, CT, and fusion hybrid imaging in patients with stable angina requiring invasive coronary angiography. Computed tomography was superior in the diagnosis of multivessel disease and the detection of the culprit vessel. SPECT was a functional complement to invasive coronary angiography in detecting the most ischemic territory. In patients with SPECT prior to invasive coronary angiography, SPECT-CT fusion imaging did not change therapeutic management.

The initial article on the EVINCI trial multicenter European protocol[71] was published. In patients with a low prevalence of coronary disease and stable angina, studied with all types of cardiac imaging techniques, the optimal diagnostic technique for evaluation of coronary artery disease was combined coronary CT and perfusion SPECT.

Quantification of Regional Blood Flow and Coronary Reserve

Absolute quantification studies of regional myocardial blood flow performed with PET acquired new relevance.[80,81] A normal quantitative value of coronary reserve practically excludes severe coronary artery disease (high negative predictive value), and quantitative evaluation of coronary reserve has a prognostic value independent of coronary anatomy, as it provides information on diffuse atherosclerosis and microvascular disease.

One of the first studies on quantification of coronary reserve using SPECT/CT offered promising data for the use of this technique in the near future.[82]

Amyloidosis

There was new information in the field of cardiac amyloidosis.[83] With the availability of the classic ^{99}mTc-pyrophosphates (which are positive in the transthyretin variants of amyloidosis) and the commercialization of various radiopharmaceuticals as PET markers specific for amyloid deposits (such as ^{18}F-florbetapir), images can be obtained of amyloid light chains in the myocardium.

Positron Emission Tomography and Computed Tomography in Endocarditis

Two studies were helpful regarding the diagnosis of infection of implantable devices (pacemakers and implantable cardioverter-defibrillators) using PET/CT with ^{18}F-fluorodeoxyglucose: they describe a very high diagnostic accuracy,[84] and the ability to demarcate the extent of infection.[85]

Figure 5. Fusion positron emission tomography/computed tomography images with ^{18}F-fluorodeoxyglucose of patients with endocarditis. A, pacemaker lead; B, Bentall procedure. C, mechanical aortic prosthesis.

The publication by Pizzi et al[86] involved a series of 92 patients with suspected prosthetic or device endocarditis investigated using gated PET with ^{18}F-fluorodeoxyglucose combined with cardiac CT angiography. These authors found that this technique made patient classification faster and easier, because it reduced the percentage of cases defined as possible endocarditis from 55% to 5%, with 95% of patients correctly classified. Sensitivity was 91% and specificity was 90.6%, being somewhat better for implantable devices (87.5% and 100.0%) than for prosthetic valves (87.2% and 92.0%). The PET/CT technique was included in the guidelines of the European Society of Cardiology as a new major criterion for endocarditis, based on its high negative predictive value in patients with prostheses beyond the first 3 months after implant[87] (Figure 5).

CONFLICTS OF INTEREST

None declared.

REFERENCES

1. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.
2. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.
3. Lancellotti P, Price S, Edvardsen E, Cosyns B, Neskovic AN, Dulgheru R, et al. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Cardiovasc Imaging. 2015;16:119–46.
4. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28:727–54.
5. Barba J, Gómez de Diego JJ, Evangelista A, Lauradogoitia E, Aguilar R, Zamorano JL, et al. La ecocardiografía fuera del ámbito de la cardiología: recomendaciones de la Sociedad Española de Cardiología para un uso adecuado de los equipos de ecocardiografía de bolsillo. Sociedad Española de Cardiología. 2014. Available at: http://www.secardiologia.es/publicaciones/catalogo/protocolos/5919-recomendaciones-sec-para-el-uso-de-equipos-de-ecocardiografia-de-bolsillo
6. Olivieri LJ, Krieger A, Loke YH, Nath DS, Kim PC, Sable CA. Three-dimensional printing of intracardiac defects from three-dimensional echocardiographic images: feasibility and relative accuracy. J Am Soc Echocardiogr. 2015;28: 392–7.
7. Farooqi KM, Sengupta PP. Echocardiography and three-dimensional printing: sound ideas to touch a heart. J Am Soc Echocardiogr. 2015;28:398–403.
8. Bisplinghoff S, Hänisch C, Becker M, Radermacher K, De la Fuente M. Fusion of coronary angiography and stress echocardiography for myocardial viability evaluation. Int J Comput Assist Radiol Surg. 2015;10:11–7.
9. Gafoor S, Schulz P, Heuer L, Matic P, Franke J, Bertog S, et al. Use of EchoNavigator, a novel echocardiography-fluoroscopy overlay system, for transseptal puncture and left atrial appendage occlusion. J Interv Cardiol. 2015;28:215–7.
10. Kornmann LM, Zernecke A, Curfs DMJ. Echogenic perfluorohexane-loaded macrophages adhere in vivo to activated vascular endothelium in mice, an explorative study. Cardiovasc Ultrasound. 2015;13:1–8.
11. Unger E, Porter T, Lindner J, Grayburn P. Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Deliv Rev. 2014;72:110–26.
12. Larsson MK, Larsson M, Nowak G, Paradossi G, Brodin LÅ, Sjöberg BJ, et al. Endocardial border delineation capability of a novel multimodal polymer-shelled contrast agent. Cardiovasc Ultrasound. 2014;12:24–31.
13. Laiq Z, Smith L, Xie F, Chamsi-Pasha M, Porter TR. Differences in patient outcomes after conventional versus real time perfusion stress echocardiography in men versus women: a prospective randomised trial. Heart. 2015;101:559–64.
14. Donal E, Lund LH, Oger E. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1093/ehjci/jev144
15. Garbi M, Chambers J, Vannan MA, Lancellotti P. Valve stress echocardiography: a practical guide for referral, procedure, reporting, and clinical implementation of results from the HAVEC Group. JACC Cardiovasc Imaging. 2015;8:724–36.
16. Schiano-Lomoriello V, Santoro C, De Simone G, Trimarco B, Galderisi M. Diastolic bicycle stress echocardiography: Normal reference values in a middle age population. Int J Cardiol. 2015;191:181–3.
17. Gaibazzi N, Porter TR, Agricola E. Prognostic value of echocardiographic calcium score in patients with a clinical indication for stress echocardiography. JACC Cardiovasc Imaging. 2015;8:389–96.
18. Chou R; High Value Care Task Force of the American College of Physicians. Cardiac screening with electrocardiography, stress echocardiography, or

myocardial perfusion imaging: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:438–47.

19. Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib G, Hoffman P, et al.; European Association of Cardiovascular Imaging. Recommendations for transoesophageal echocardiography: EACVI update 2014. Eur Heart J Cardiovasc Imaging. 2014;15:353–65.

20. Pressman GS, Movva R, Topilsky Y, Clavel MA, Saldanha JA, Watanabe N, et al. Mitral annular dynamics in mitral annular calcification: a three-dimensional imaging study. J Am Soc Echocardiogr. 2015;28:786–94.

21. Badano LP, Cucchini U, Muraru D, Al Nono O, Sarais C, Iliceto S. Use of three-dimensional speckle tracking to assess left ventricular myocardial mechanics: inter-vendor consistency and reproducibility of strain measurements. Eur Heart J Cardiovasc Imaging. 2013;14:285–93.

22. Altman M, Bergerot C, Aussoleil A, Davidsen ES, Sibellas F, Ovize M, et al. Assessment of left ventricular systolic function by deformation imaging derived from speckle tracking: a comparison between 2D and 3D echo modalities. Eur Heart J Cardiovasc Imaging. 2014;15:316–23.

23. Seo Y, Ishizu T, Kawamura R, Yamamoto M, Kuroki K, Igarashi M, et al. Three-dimensional propagation imaging of left ventricular activation by speckle-tracking echocardiography to predict responses to cardiac resynchronization therapy. J Am Soc Echocardiogr. 2015;28:606–14.

24. Perez de Isla L, Feltes G, Moreno J, Martinez W, Saltijeral A, De Agustin JA, et al. Quantification of left atrial volumes using three-dimensional wall motion tracking echocardiographic technology: comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2014;15:793–9.

25. Montserrat S, Gabrielli L, Borras R, Poyatos S, Berruezo A, Bijnens B, et al. Left atrial size and function by three-dimensional echocardiography to predict arrhythmia recurrence after first and repeated ablation of atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2014;15:515–22.

26. Charakida M, Pushparajah K, Anderson D, Simpson JM. Insights gained from three-dimensional imaging modalities for closure of ventricular septal defects. Circ Cardiovasc Imaging. 2014;7:954–61.

27. Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7:1251–65.

28. Yosefy C, Laish-Farkash A, Azhibekov Y, Khalameizer V, Brodkin B, Katz A. A new method for direct three-dimensional measurement of left atrial appendage dimensions during transesophageal echocardiography. Echocardiography. 2015. Available at: http://dx.doi.org/10.1111/echo.12983.

29. Jaguszewski M, Manes C, Puippe G, Salzberg S, Müller M, Falk V, et al. Cardiac CT and echocardiographic evaluation of peri-device flow after percutaneous left atrial appendage closure using the AMPLATZER cardiac plug device. Catheter Cardiovasc Interv. 2015;85:306–12.

30. Quader N, Davidson CJ, Rigolin VH. Percutaneous closure of perivalvular mitral regurgitation: how should the interventionalists and the echocardiographers communicate? J Am Soc Echocardiogr. 2015;28:497–508.

31. Kamperidis V, Van Rosendael PJ, Katsanos S, Van der KF, Regeer M, Al Amri I, et al. Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data. Eur Heart J. 2015;36:2087–96.

32. Dahl JS, Eleid MF, Pislaru SV, Scott CG, Connolly HM, Pellikka PA. Development of paradoxical low-flow, low-gradient severe aortic stenosis. Heart. 2015;101: 1015–23.

33. Kusunose K, Goodman A, Parikh R, Barr T, Agarwal S, Popovic ZB, et al. Incremental prognostic value of left ventricular global longitudinal strain in patients with aortic stenosis and preserved ejection fraction. Circ Cardiovasc Imaging. 2014;7:938–45.

34. Dahou A, Bartko PE, Capoulade R, Clavel MA, Mundigler G, Grondin SL, et al. Usefulness of global left ventricular longitudinal strain for risk stratification in low ejection fraction, low-gradient aortic stenosis: results from the multicenter True or Pseudo-Severe Aortic Stenosis study. Circ Cardiovasc Imaging. 2015; 8:e002117.

35. Dulgheru R, Magne J, Davin L, Nchimi A, Oury C, Pierard LA, et al. Left ventricular regional function and maximal exercise capacity in aortic stenosis. Eur Heart J Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1093/ehjci/jev147

36. Yotti R, Bermejo J, Gutierrez-Ibanes E, Perez D, Mombiela T, Elizaga J, et al. Systemic vascular load in calcific degenerative aortic valve stenosis: insight from percutaneous valve replacement. J Am Coll Cardiol. 2015;65:423–33.

37. Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka PA. Survival by stroke volume index in patients with low-gradient normal EF severe aortic stenosis. Heart. 2015;101:23–9.

38. Garcia-Martin A, Lazaro-Rivera C, Fernandez-Golfin C, Salido-Tahoces L, Moya-Mur JL, Jimenez-Nacher JJ, et al. Accuracy and reproducibility of novel echo-cardiographic three-dimensional automated software for the assessment of the aortic root in candidates for thanscatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1093/ehjci/jev20

39. Islas F, Almeria C, Garcia-Fernandez E, Jimenez P, Nombela-Franco L, Olmos C, et al. Usefulness of echocardiographic criteria for transcatheter aortic valve implantation without balloon predilation: a single-center experience. J Am Soc Echocardiogr. 2015;28:423–9.

40. Orwat S, Diller GP, Kaleschke G, Kerckhoff G, Kempny A, Radke RM, et al. Aortic regurgitation severity after transcatheter aortic valve implantation is underestimated by echocardiography compared with MRI. Heart. 2014; 100:1933–8.

41. Ribeiro HB, Le VF, Larose E, Dahou A, Nombela-Franco L, Urena M, et al. Cardiac magnetic resonance versus transthoracic echocardiography for the assessment

and quantification of aortic regurgitation in patients undergoing transcatheter aortic valve implantation. Heart. 2014;100:1924–32.

42. Mantovani F, Clavel MA, Vatury O, Suri RM, Mankad SV, Malouf J, et al. Cleft-like indentations in myxomatous mitral valves by three-dimensional echocardiographic imaging. Heart. 2015;101:1111–7.

43. Debonnaire P, Al Amri I, Leong DP, Joyce E, Katsanos S, Kamperidis V, et al. Leaflet remodelling in functional mitral valve regurgitation: characteristics, determinants, and relation to regurgitation severity. Eur Heart J Cardiovasc Imaging. 2015;16:290–9.

44. Franco E, Almeria C, De Agustin JA, Arreo DV, Gomez de Diego JJ, Garcia Fernandez MA, et al. Three-dimensional color Doppler transesophageal echocardiography for mitral paravalvular leak quantification and evaluation of percutaneous closure success. J Am Soc Echocardiogr. 2014;27:1153–63.

45. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2015;28:119–82.

46. Caballero L, Kou S, Dulgheru R, Gonjilashvili N, Athanassopoulos GD, Barone D, et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1093/ehjci/jev083

47. Orii M, Hirata K, Tanimoto T, Shiono Y, Shimamura K, Ishibashi K, et al. Two-dimensional speckle tracking echo for the prediction of reversible myocardial dysfunction after acute myocardial infarction: comparison with magnetic resonance imaging. Echocardiography. 2015;32:768–78.

48. Park JH, Kusunose K, Motoki H, Kwon DH, Grimm RA, Griffin BP, et al. Assessment of right ventricular longitudinal strain in patients with ischemic cardio-myopathy: head-to-head comparison between two-dimensional speckle-based strain and velocity vector imaging using volumetric assessment by cardiac magnetic resonance as a "gold standard". Echocardiography. 2015;32:956–65.

49. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28:183–93.

50. Yang H, Marwick TH. Improvement in strain concordance between two major vendors after the strain standardization initiative. J Am Soc Echocardiogr. 2015;28:642–8.

51. Galderisi M, Cardim N, D'Andrea A, Bruder O, Cosyns B, Davin L, et al. The multi-modality cardiac imaging approach to the Athlete's heart: an expert consensus of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:353.

52. Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D'Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hyper-trophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280.

53. Peteiro J, Fernandez X, Bouzas-Mosquera A, Monserrat L, Méndez C, Rodriguez-Garcia E. Exercise echocardiography and cardiac magnetic resonance imaging to predict outcome in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:423–32.

54. Urbano-Moral JA, López-Haldón JE. Aspectos poco conocidos de la miocardiopatía hipertrófica. Rev Esp Cardiol. 2015;68:554–8.

55. Urbano-Moral JA, Gangadharamurthy D, Comenzo RL, Pandian NG, Patel AR. Ecocardiografía *speckle tracking* (rastreo de marcas) tridimensional en la amiloidosis cardiaca de cadenas ligeras: estudio de los parámetros de mecánica miocárdica ventricular izquierda y derecha. Rev Esp Cardiol. 2015;68:657–64.

56. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.

57. Bordun KA, Premecz S, DaSilva M, Mandal S, Goyal V, Glavinovic T. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizu-mab and sunitinib mediated cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309:H692–701.

58. Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, et al. Comprehensive echocardiographic detection of treatment-related cardiac dys-function in adult survivors of childhood cancer. Results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65:2511–22.

59. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15:324–31.

60. Garbi M, McDonagh T, Cosyns B, Bucciarelli-Ducci C, Edvardsen T, Kitsiou A, et al.; EACVI Imaging Task Force. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging. 2015;16:147–53.

61. Hasselberg NE, Haugaa KH, Sarvari SI, Gullestad L, Andreassen AK, Smiseth OA, et al. Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction. Eur Heart J Cardiovasc Imaging. 2015;16:217–24.

62. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132:402–14.

63. Maruo T, Seo Y, Yamada S, Arita T, Ishizu T, Shiga T, et al. The Speckle Tracking Imaging for the Assessment of Cardiac Resynchronization Therapy (START) study. Circ J. 2015;79:613–22.

64. Rodríguez-Palomares JF, Ortiz-Pérez JT, Lee DC, Bucciarelli-Ducci C, Tejedor P, Bonow RO, et al. Time elapsed after contrast injection is crucial to determine infarct transmurality and myocardial functional recovery after an acute myocardial infarction. J Cardiovasc Magn Reson. 2015;30:17–43.

65. Garcia-Dorado D, Garcia-del-Blanco B, Otaegui I, Rodríguez-Palomares J, Pineda V, Gimeno F, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014;177:935–41.

66. Eitel I, De Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;64:1217–26.

67. Van Kranenburg M, Magro M, Thiele H, De Waha S, Eitel I, Cochet A, et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7:930–9.

68. Takx RA, Blomberg BA, El Aidi H, Habets J, De Jong PA, Nagel E, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1161/CIRCIMAGING.114.002666.

69. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95.

70. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1161/CIRCIMAGING.114.003073.

71. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, et al.; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015. Available at: http://dx.doi.org/10.1161/CIRCIMAGING.114.002179.

72. Rochitte CE, George RT, Chen MY, Arbab-Zadeh A, Dewey M, Miller JM, et al. Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study. Eur Heart J. 2014;35:1120–30.

73. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al.; PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291–300.

74. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick TR, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging. 2015;16:441–8.

75. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385:2383–91.

76. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, et al. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol. 2014;64:1202–13.

77. Romero-Farina G, Candell-Riera J, Aguadé-Bruix S, Ferreira-González I, Cuberas-Borrós G, Pizzi N, et al. Warranty periods for normal myocardial perfusion stress SPECT. J Nucl Cardiol. 2015;22:44–54.

78. Romero-Farina G, Candell-Riera J, Ferreira-González I, Aguadé-Bruix S, Pizzi N, García-Dorado D. Normal myocardial perfusion gated SPECT and positive stress test: different prognoses in women and men. J Nucl Cardiol. 2015;22:453–65.

79. Pizzi MN, Aguadé-Bruix S, Roque A, Cuéllar-Calabria H, Romero-Farina G, García del Blanco B, et al. SPECT, angio-TC coronaria, coronariografía invasiva e imágenes de fusión en la cardiopatía isquémica estable. Rev Esp Med Nucl Imagen Mol. 2015;34:173–80.

80. Naya M, Murthy VL, Taqueti VR, Foster CR, Klein J, Garber M, et al. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography. J Nucl Med. 2014;55:248–55.

81. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131:19–27.

82. Hsu B, Chen FC, Wu TC, Huang WS, Hou PN, Chen CC, et al. Quantitation of myocardial blood flow and myocardial flow reserve with ^{99m}Tc-sestamibi dynamic SPECT/CT to enhance detection of coronary artery disease. Eur J Nucl Med Mol Imaging. 2014;41:2294–306.

83. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7:552–62.

84. Ahmed FZ, James J, Cunnington C, Motwani M, Fullwood C, Hooper J, et al. Device generator pocket infection using ^{18}F-FDG-PET/CT. Eur Heart J Cardiovasc Imaging. 2015;16:521–30.

85. Tlili G, Amroui S, Mesguich C, Rivière A, Bordachar P, Hindié E, et al. High performances of ^{18}F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients. J Nucl Cardiol. 2015;2:787–98.

86. Pizzi MN, Roque A, Fernández-Hidalgo N, Cuéllar-Calabria H, Ferreira-González I, González-Alujas MT, et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with ^{18}F-fluordeoxyglucose positron emission tomography/computed tomography angiography: initial results at an infective endocarditis referral center. Circulation. 2015;132:1113–26.

87. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36:3075–128.